Urology

Editor's Choice

Making good decisions requires that physicians have reliable and practical data. Comparative effectiveness reviews and objective findings on different medical interventions and strategies, as provided by the Agency for Healthcare Research and Quality in its Effective Health Care Program, can help physicians make the most informed choices among treatment options.

LATEST ARTICLES

Tadalafil (Cialis): A phosphodiesterase type 5 inhibitor for the treatment of benign prostatic hyperplasia

New indication: Tadalafil once-daily 5-mg oral tablet is FDA approved for the treatment of benign prostatic hyperplasia (BPH) in patients with or without erectile dysfunction (ED).

Urologists face cloud of uncertainty in 2012

Staring down a possible 27% reimbursement cut, questions about the viability of health care reform, increasing demand for their services, and a shrinking work force, it's less than surprising that urologists are anxious about the prospects for their profession.

Effective Health Care Clinician Guides

American Urological Association: 5-ARI, alpha-blocker differ in number of BPH-related complications

The 5-alpha-reductase inhibitor dutasteride is associated with markedly lower BPH-related complication rates than the alpha-blocker tamsulosin, according to analysis of 2 large trials.

American Urological Association: Overactive bladder agent demonstrates efficacy, tolerability in phase 3 trial

The selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolderated, according to results of a phase 3 study.